Patents by Inventor Robert Selliah

Robert Selliah has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 3-aryl-substituted quinazolones, and uses thereof
    Patent number: 8575143
    Abstract: Compounds represented by Structural Formula (I): are useful, for example, in the effective killing or reducing the rate of proliferation of cancer cells, such as in patients suffering from cancer. In addition to the compounds themselves, the invention provides pharmaceutical compositions of the compounds and method of treatment using the compounds.
    Type: Grant
    Filed: December 22, 2006
    Date of Patent: November 5, 2013
    Assignee: Prolexys Pharmaceuticals, Inc.
    Inventors: Longwu Qi, Raj Gopal Venkat, Michael Pierce, Paul B. Robbins, Sudhir R. Sahasrabudhe, Robert Selliah
  • Quinoxaline derivatives as antitumor agents
    Patent number: 8518959
    Abstract: The invention relates to methods of screening for binding partners, especially binding partners essential for the biological activity of erastin (e.g. VDACs such as VDAC3). The invention also provides reagents and methods for effective killing of cancer cells with erastin and related compounds or derivatives.
    Type: Grant
    Filed: January 25, 2006
    Date of Patent: August 27, 2013
    Assignee: Prolexys Pharmaceuticals, Inc.
    Inventors: Robert R. Becklin, Cindy Lou Chepanoske, John M. Peltier, Longwu Qi, Paul B. Robbins, Sudhir R. Sahasrabudhe, Robert Selliah, Keith Simmon, Brent R. Stockwell, Raj Gopal Venkat, Moritz von Rechenberg, Eugene Y. Zhen
  • Inhibitors of P38 and Methods of Using the Same
    Publication number: 20110301160
    Abstract: In general, the present invention relates to compounds capable of inhibiting p38 in vivo or in vitro, and methods for treating conditions associated with p38 activity or cytokine activity.
    Type: Application
    Filed: December 3, 2010
    Publication date: December 8, 2011
    Applicant: ARQULE, INC.
    Inventors: Mark A. ASHWELL, Syed ALI, Jifeng LIU, Yanbin LIU, Peter LOHSE, Belew MEKONNEN, Robert SELLIAH, Manish TANDON, Woj WRONA, Valery ANTONENKO
  • 3-Aryl-Substituted Quinazolones, and Uses Thereof
    Publication number: 20110092489
    Abstract: Compounds represented by Structural Formula (I): are useful, for example, in the effective killing or reducing the rate of proliferation of cancer cells, such as in patients suffering from cancer. In addition to the compounds themselves, the invention provides pharmaceutical compositions of the compounds and method of treatment using the compounds.
    Type: Application
    Filed: December 22, 2006
    Publication date: April 21, 2011
    Applicant: Prolexys Pharmaceuticals ,Inc.
    Inventors: Longwu QI, Raj Gopal Venkat, Michael Pierce, Paul B. Robbins, Sudhir R. Sahasrabudhe, Robert Selliah
  • Inhibitors of P38 and methods of using the same
    Patent number: 7902192
    Abstract: In general, the present invention relates to compounds capable of inhibiting p38, methods for inhibiting p38 in vivo or in vitro, and methods for treating conditions associated with p38 activity or cytokine activity.
    Type: Grant
    Filed: May 14, 2004
    Date of Patent: March 8, 2011
    Assignee: ArQule, Inc.
    Inventors: Mark A. Ashwell, Syed Ali, Jifeng Liu, Yanbin Liu, Peter Lohse, Belew Mekonnen, Robert Selliah, Manish Tandon, Woj Wrona, Valery Antonenko
  • Erastin and erastin binding proteins, and uses thereof
    Patent number: 7615554
    Abstract: The invention relates to methods of screening for binding partners, especially binding partners essential for the biological activity of erastin (e.g. VDACs such as VDAC3). The invention also provides reagents and methods for effective killing of cancer cells with erastin and related compounds or derivatives.
    Type: Grant
    Filed: January 25, 2006
    Date of Patent: November 10, 2009
    Assignees: Prolexys Pharmaceuticals, Inc., Whitehead Institute for Biomedical Research, The Trustees of Columbia University in the City of New York
    Inventors: Robert Selliah, Longwu Qi, Paul B. Robbins, Sudhir R. Sahasrabudhe, Brent R. Stockwell, Raj Gopal Venkat
  • Quinoxaline Derivatives as Antitumor Agents
    Publication number: 20090214465
    Abstract: The invention relates to methods of screening for binding partners, especially binding partners essential for the biological activity of erastin (e.g. VDACs such as VDAC3). The invention also provides reagents and methods for effective killing of cancer cells with erastin and related compounds or derivatives.
    Type: Application
    Filed: January 25, 2006
    Publication date: August 27, 2009
    Applicants: PROLEXYS PHARMACEUTICALS, INC., WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH, THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF
    Inventors: Robert R. Becklin, Cindy Lou Chepanoske, John M. Peltier, Longwu Qi, Paul B. Robbins, Sudhir R. Sahasrabudhe, Robert Selliah, Keith Simmon, Brent R. Stockwell, Raj Gopal Venkat, Moritz von Rechenberg, Eugene Y. Zhen
  • Fused Pyrimidones and Thiopyrimidones, and Uses Thereof
    Publication number: 20090170834
    Abstract: Compounds represented by Structural Formula (I): are useful, for example, in the effective killing or reduction in rate of proliferation of cancer cells, such as in patients suffering from cancer. In addition to the compounds themselves, the invention provides pharmaceutical compositions of the compounds and method of treatment using the compounds.
    Type: Application
    Filed: December 22, 2006
    Publication date: July 2, 2009
    Applicant: PROLEXYS PHARMACEUTICALS, INC.
    Inventors: Raj Gopal Venkat, Longwu Qi, Michael Pierce, Paul B. Robbins, Sudhir R. Sahasrabudhe, Robert Selliah
  • Non-peptidyl agents with pHSP20-like activity, and uses thereof
    Publication number: 20090136561
    Abstract: The present invention provides compositions and methods for modulating smooth muscle cells. The present invention also provides methods of identifying small molecule candidate therapeutic agents for modulating smooth muscle.
    Type: Application
    Filed: October 20, 2008
    Publication date: May 28, 2009
    Applicant: Prolexys Pharmaceuticals, Inc.
    Inventors: Moritz von Rechenberg, John M. Peltier, Sudhir R. Sahasrabudhe, Srdjan Askovic, Robert Selliah, Thomas Zarembinski
  • Inhibitors of P38 and Methods of Using the Same
    Publication number: 20070270418
    Abstract: In general, the present invention relates to compounds capable of inhibiting p38, methods for inhibiting p38 in vivo or in vitro, and methods for treating conditions associated with p38 activity or cytokine activity.
    Type: Application
    Filed: May 14, 2004
    Publication date: November 22, 2007
    Inventors: Mark Ashwell, Syed Ali, Jifeng Liu, Yanbin liu, Peter Lohse, Belew Mekonnen, Robert Selliah, Manish Tandon, Woj Wrona, Valery Antonenko
  • Erastin and erastin binding proteins, and uses thereof
    Publication number: 20060211683
    Abstract: The invention relates to methods of screening for binding partners, especially binding partners essential for the biological activity of erastin (e.g. VDACs such as VDAC3). The invention also provides reagents and methods for effective killing of cancer cells with erastin and related compounds or derivatives.
    Type: Application
    Filed: January 25, 2006
    Publication date: September 21, 2006
    Applicants: Prolexys Pharmaceuticals Inc., Whitehead Institute for Biomedical Research, The Trustees of Columbia University in the City of New York
    Inventors: Robert Selliah, Longwu Qi, Paul Robbins, Sudhir Sahasrabudhe, Brent Stockwell, Raj Venkat
  • Non-peptidyl agents with pHSP20-like activity, and uses thereof
    Publication number: 20050187268
    Abstract: The present invention provides compositions and methods for modulating smooth muscle cells. The present invention also provides methods of identifying small molecule candidate therapeutic agents for modulating smooth muscle.
    Type: Application
    Filed: February 23, 2005
    Publication date: August 25, 2005
    Applicant: Prolexys Pharmaceuticals Inc.
    Inventors: Moritz von Rechenberg, John Peltier, Sudhir Sahasrabudhe, Srdjan Askovic, Robert Selliah, Thomas Zarembinski